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Erug Therapy for
ypercholesterolemia
ime to End the Double Standard
n his Viewpoint paper regarding atherosclerosis screening, Shah (1)
ecries the “double standard” of requiring proof of clinical benefit for
maging studies but not for clinical risk scores. However, a far more
roublesome double standard relates to the treatment of hypercholes-
erolemia versus the treatment of other modifiable cardiovascular risk
actors. The initiation of drug therapy for hypertension, diabetes, and
igarette smoking is not dependent on any calculation of the estimated
isk of developing a hard cardiovascular end point within an arbitrary
ime period. Those with hypertension or diabetes who do not reach
heir treatment goals with lifestyle modification alone or those who
re unable to quit smoking “cold turkey” are appropriately treated with
rug therapy. In fact, the Seventh Report of the Joint National
ommittee on Prevention, Detection, Evaluation, and Treatment of
igh Blood Pressure (JNC 7) explicitly states that it “does not stratify
ypertensive individuals by the presence or absence of risk factors
. . . in order to make different treatment recommendations . . . . JNC
suggests that all people with hypertension . . . be treated” (2).
mong the modifiable cardiovascular risk factors, only hypercholes-
erolemia requires anything other than the presence of the risk factor
tself to prompt treatment.
Shah (1) explicitly raises this issue himself, but dismisses the
nconditional treatment of hypercholesterolemia with statins because
f concerns regarding cost, need for lifetime use, and intolerance.
owever, these concerns are certainly no different than those associ-
ted with drug treatment for hypertension or diabetes, issues not
ddressed by Shah (1). Moreover, statins are among the safest
edications ever introduced (3) and are generally no more expensive
r risky than many widely prescribed antihypertensive and antidiabetic
rugs. Most remarkably, Shah (1) is not in favor of unconditional
reatment of hypercholesterolemia, in part because statin therapy
only addresses about 30% to 50% of the risk.” It is difficult to
nderstand why a reduction of risk of this magnitude for a condition
hat accounts for nearly one-third of all deaths worldwide would
epresent anything other than a powerful endorsement of treatment. It
s time to embrace the unconditional treatment of hypercholesterol-
mia and bring lipid treatment in line with the well-established
reatment paradigms for other cardiovascular risk factors.
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eply
appreciate the comments by Dr. Cooper regarding my Viewpoint
aper (1). I fully concur with Dr. Cooper that 30% to 50% relative
ardiovascular risk reduction with statins is a highly clinically worth-
hile benefit, but I beg to differ that unconditional treatment of
veryone without known atherothrombotic cardiovascular disease and
yperlipidemia with a statin is appropriate. It is an established fact
hat atherothrombotic cardiovascular disease does not develop in a
ignificant proportion of subjects with hyperlipidemia, and, con-
ersely, a significant proportion of subjects with atherothrombotic
ardiovascular disease do not have hyperlipidemia; in fact, the real
efinition of what constitutes hyperlipidemia is itself unclear. If the
oal of using a statin is to reduce atherothrombotic cardiovascular
vents, then it is unrealistic to expect those patients without significant
therosclerosis to benefit from statin therapy even if they have
yperlipidemia; in such subjects, one can only expect side effects and
xtra costs associated with statin use. Fortunately, we now have the
bility to identify subclinical atherosclerosis in 2 major vascular beds
oninvasively so that those patients without atherosclerosis can be
bserved and reassessed while adopting a healthy lifestyle without
esorting to statin therapy. Because hypertension has adverse effects
eyond simply an association with atherosclerosis, such as increased
isk of stroke, especially hemorrhagic stroke, renal failure, congestive
eart failure, and aortic aneurysm formation, one cannot equate
yperlipidemia management with hypertension management. Simi-
arly, smoking-associated health risk includes lung disease, cancer, and
hrombotic cardiovascular events even with minimal atherosclerosis;
moking cessation is advisable for every smoker regardless of other risk
actors. In this day and age, where we are headed toward the concept
f “personalized medicine” (matching treatment to underlying risk
nd disease phenotype rather than a “one size fits all” strategy, which
as been the prevailing paradigm), the approach outlined in my
iewpoint paper is a step in that direction.
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isinterpretation of
rostate Cancer Data
n a recent issue of the Journal, Lauer (1) suggested that the lack
f effect of prostate-specific antigen (PSA) screening for prostate
ancer is an important reason to be cautious about screening for
ubclinical coronary artery disease. Unfortunately, his argument
ight be fallacious. First, he states that prostate cancer death rates
ave not declined, despite widespread screening. Quite the con-
rary is true. Death rates due to prostate cancer have substantially
eclined in the U.S. from 39.2 to 23.6/100,000 from 1992 to 2006
2–4). This is an age-adjusted decline of approximately 4%/year.
rom 1991 to 2004, prostate cancer mortality has declined much
ore rapidly in the U.S. with the frequent use of PSA testing than
n the United Kingdom, where there is less screening (4.2%/year in
he U.S. vs. 1.1%/year in the United Kingdom) (5).
Second, he points to the recent report of the PLCO (Prostate,
ung, Colorectal and Ovarian Cancer Screening Trial) that failed
o document benefit of prostate cancer screening with PSA (6).
nfortunately, the PLCO trial was contaminated by high screen-
ng rates in the comparison group and a lack of control for
herapies for prostate cancer. It is estimated that probably 50% of
en 50 years of age and older in the U.S. have a PSA test. Most
ecently, PSA testing was evaluated in a population that was
reviously unexposed to PSA testing. A randomized trial of 20,000
en in Göteborg, Sweden, 50 to 64 years of age at entry were
ollowed an average of 14 years (7). The reduction of prostate
ancer deaths was 40% (range 0.17 to 64) in the PSA screening
ersus control group, p  0.002. Approximately 293 men needed
o be screened and 12 needed to be diagnosed to prevent 1 prostate
ancer death—44 deaths in the intervention versus 78 in the
ontrol group. The effect of PSA testing on reducing mortality in
his study was of similar magnitude as mammography screening for
reast cancer.
A trial to evaluate screening of asymptomatic individuals for the
revention of subsequent clinical coronary artery disease events
i.e., screening asymptomatic individuals with coronary calcium
etection) is impractical. The technology is widely available; its
rognostic implications are well-published; and preventive thera-
ies such as lipid lowering, antihypertensive therapy, and lifestyle
odifications are now accessible and affordable. Such a trial, like
he PLCO trial, will be contaminated by crossovers, use or lack of
se of statins and other effective therapies, and poor compliance
ith dietary and pharmacological therapies. The trial of hard end
oints (i.e., coronary heart disease [CHD] deaths or myocardial
nfarction), will require long follow-up because of the early stage of
ncubation of atherosclerosis in which these individuals will be
etected. Do we really need to prove that lipid lowering is effective
n individuals with atherosclerosis for reducing CHD mortality?
o we need to waste another 7 to 10 years and millions of dollars
f valuable research funds? The key is maximizing the use of
roven effective preventive pharmacological and nonpharmacologi- nal therapies by targeting the population most likely to benefit
rom them and thereby substantially reducing CHD incidence,
ortality, and costs of health care.
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eply
n their thoughtful letter, Drs. Kuller and Edmundowicz challenge
y call for randomized trials of coronary artery screening (1). They
ite U.S./United Kingdom ecological data demonstrating public
ealth benefits from prostate-specific antigen (PSA) screening (2)
nd then cite a just-published randomized trial that found reduced
ortality (3). They argue that, in our current environment, it is
mpractical to execute trials, and even so, they are unnecessary: we
lready know lipid-lowering therapy works.
Numerous authorities have cited the limitations of observational
nalyses of screening; these include lead- and length-time bias,
isattribution bias, and overdiagnosis. Even Collin et al. (2), who
rote the positive ecological study that Kuller and Edmundowicz
ite, conclude their report stating, “We can only continue to
peculate about the relative contributions of differences in detec-
ion and treatment or the relative balance of benefits and harms,
ntil the publication of findings from trials provides the robust
vidence that is so eagerly awaited.” I agree!
Prostate cancer kills far less often than coronary artery disease,
et academic leaders have completed large-scale trials. Two trials
hat enrolled approximately 250,000 patients showed little or no
enefit and much overdiagnosis, whereas 1 trial an order of
agnitude smaller suggests benefit in some patients (3). Academic
eaders have performed screening trials for other less common
iseases, including breast cancer, lung cancer, and aortic aneurysm.
urely we can execute a screening trial for coronary disease, the
ation’s leading cause of death.
